Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053350 · ClinicalTrials.gov registry record · Phase 2
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02053350 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 7 participants.
The verdict
NCT02053350, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the treatment of C. difficile infection. We hypothesize that alanyl-glutamine when given with standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality and recurrent disease.
Interventions
- DRUG Alanyl-glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053350
The ClinicalTrials.gov registry entry for NCT02053350 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alanyl-glutamine is the first listed.
NCT02053350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053350 about?
NCT02053350 is a clinical study titled "Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection". The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the treatment of C. difficile infection. We hypothesize that alanyl-glutamine when given with standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality and recurrent disease.
What is the current status of trial NCT02053350?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-04. Estimated completion is 2017-04-05.
What interventions are being tested in trial NCT02053350?
The interventions under investigation include: Alanyl-glutamine (DRUG).
Who is sponsoring clinical trial NCT02053350?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.